Trade Kura Oncology Inc - KURA CFD

Kura Oncology Inc Company profile

About Kura Oncology Inc

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Kura Oncology Inc revenues was not reported. Net loss increased 46% to $130.5M. Higher net loss reflects General and administrative - Balancing increase of 35% to $30.4M (expense), Stock-based Compensation in SGA increase of 82% to $16.1M (expense), Share-based compensation increase of 88% to $7.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.69 to -$1.97.